Information Provided By:
Fly News Breaks for May 24, 2019
May 24, 2019 | 05:25 EDT
RBC Capital analyst Brian Abrahams downgraded BioCryst Pharmaceuticals to Sector Perform from Outperform and lowered his price target for the shares to $4.50 from $16.
News For BCRX From the Last 2 Days
There are no results for your query BCRX